PolyPid Third Quarter 2026 Conference Call - POLYPID LTD

Explicit Guidance:

• Cash Runway: Management expects existing cash resources ($15.5M at Sept 30, 2026, plus $15M NDA milestone receivable), partnership proceeds, and potential future milestones to be sufficient to fund operations through 2028.
• NTAP Decision Timing: Anticipated CMS decision on the New Technology Add-on Payment (NTAP) for D-Plex 100 expected in August 2027; if granted, effective impact expected by October 2027.
• Milestone Payments: Potential milestone payments up to $290 million (development, regulatory, and sales) remain outstanding from the Azurity partnership, in addition to the already received $30 million.

Business-Segment Outlook:

• D-Plex 100 (Colorectal): U.S. commercial launch with partner Azurity projected for early 2027, subject to FDA approval; market access expected to ramp account-by-account over several months post-launch.
• D-Plex 100 (Label Expansion): FDA communications regarding expansion into broader abdominal surgeries (GI procedures, hysterectomies; ~4M US surgeries/year) planned to initiate in Q4 2026; potential future expansion into soft tissue and bone surgery to follow based on joint prioritization with Azurity.
• Europe (D-Plex 100): EMA marketing authorization application (MAA) validation completed with formal review underway; decision expected in H2 2027 and potential launch in 2028.
• Canada (D-Plex 100): New drug submission planned for 2027 under the existing Azurity collaboration.
• PD-01B (DFI): First-in-human (FIH) study for diabetic foot infections targeted for H2 2027, following a pre-IND meeting; development spending for the next 18 months described as "relatively modest."
• PD-03A (Obesity): Long-acting obesity program remains in early preclinical development.
• Commercial Structure: PolyPID retains full European commercialization rights after terminating the 2022 Advanced Pharma agreement; active discussions ongoing for potential new European commercial partners.

Market and Competitive Outlook:

• Adoption Drivers: Market research indicates ~90% willingness among hospital pharmacists to place D-Plex 100 on formulary; NTAP could drive this to 100%.
• Target Customer: Focus on academic centers and competitive hospitals where surgeons seek leading technology to differentiate against peers; initial launch targets high-volume colorectal and GI procedures.
• Product Profile Surgeon Feedback: Key physician adoption drivers include 60% reduction in surgical site infections (SSI) and reduction in infection complexity/severity compared to current standards.
• Pricing Strategy: Final pricing decisions and net cost per procedure disclosure will be managed by Azurity at launch; product economics aligned with hospital savings from preventing infections and reducing length of stay.

Macro / Industry Outlook:

• Regulatory Environment: NDA for D-Plex 100 is under priority review with labeling discussions underway; FDA pre-approval inspection conducted, though specific status details not disclosed prior to decision.
• Reimbursement Structure: Anticipated NTAP could cover up to 75% of product cost above standard DRG payments, significantly improving reimbursement economics for hospital patients.

Strategic Initiatives:

• U.S. Commercialization: Azurity building national sales force (200+ colleagues), medical affairs, and supply chain teams to support the early 2027 launch.
• Pipeline Expansion: Transitioning from infection prevention (D-Plex) to treatment (PD-01B) for diabetic foot infections, leveraging same active ingredient (doxycycline) and safety database.
• Partnership Levers: Three primary growth strategies for 2030 vision: (1) Maximize D-Plex 100 via label expansion and geographic expansion; (2) Expand D-Plex into new territories (Europe, Canada); (3) Grow kinetics pipeline (PD-01B, PD-03A).
• Market Access Tactic: Preparation for small-scale pilot studies (7–10 patients) at select hospitals to validate usability and workflow integration prior to broad formulary adoption.

Risks and Headwinds to Outlook:

• Regulatory Approval Uncertainty: All commercial timelines (U.S. and EU launches) and milestone payments are contingent upon FDA approval of D-Plex 100 and EMA acceptance/decision.
• Label Expansion Complexity: Future indications beyond colorectal surgery depend on FDA feedback regarding additional safety data and proof requirements; parallel vs. sequential execution timelines not yet defined.
• Supply Chain/Manufacturing: Pre-approval inspection status details withheld to avoid influencing the review, though management states no known compliance issues (Form 483) are outstanding.
• Adoption Speed: Hospital formulary processes vary in cadence (monthly to quarterly reviews), creating a stepwise adoption ramp rather than an immediate market entry.

Management Tone on the Future:

• Confidence: High confidence in execution, describing the PDUFA date (Nov 28) as a "defining moment" and stating the company is "well positioned" for the next stage.
• Strategic Clarity: Clear pivot from R&D phase to commercialization, emphasizing the "process" of launch and the strategic value of the Azurity partnership.
• Hedges: All forward statements are explicitly tied to regulatory approval; management avoids specific timing for label expansion requirements until after FDA feedback.

Miscellaneous:

• Date of Call: November 11, 2026 (Financials for Q3 ended Sept 30, 2026).
• Recent Data: Late-breaking microbiology data presented at ID Week 2026 (SHIELD2 results) showing infection reduction context.
• Financial Performance: Net loss of $5.8M in Q3 2026 (down from $7.5M in Q3 2025); R&D expenses increased to $6.5M due to NDA and commercial readiness; G&A decreased to $1.5M due to lower non-cash option expenses.